{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T01:34:11Z","timestamp":1793151251350,"version":"4.5.0"},"reference-count":27,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Objective.<\/jats:bold>\n                    Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) play a role in management of type 2 diabetes (T2D) and obesity by promoting glycemic control and weight reduction. Beyond these benefits, GLP-1 RAs have demonstrated positive effects on cardiovascular, renal, and neurological health, with emerging evidence supporting their therapeutic potential in conditions such as chronic kidney disease, asthma, obstructive sleep apnea, Parkinson\u2019s disease, and Alzheimer\u2019s disease. However, their widespread clinical use is often hindered by gastrointestinal side effects including nausea, anorexia, vomiting, and diarrhea that limit adherence and dose titration. Effective management of these adverse effects is essential to optimize treatment outcomes and maintain long-term therapy.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Case report.<\/jats:bold>\n                    A 72-year-old woman with a history of cognitive impairment, T2D, atrial fibrillation, obesity, and mood disorders presented with persistent gastrointestinal symptoms while receiving semaglutide. Dose escalation was restricted due to severe nausea, vomiting, and diarrhea, which markedly affected her quality of life. To manage these symptoms, mirtazapine was initiated. Following its introduction, the patient reported significant improvement in gastrointestinal tolerance enabling continued semaglutide therapy and successful dose advancement. Additional benefits included enhanced mood, better sleep, and overall well-being. No adverse effects related to mirtazapine were observed throughout the treatment.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion.<\/jats:bold>\n                    This case suggests that mirtazapine may be beneficial in mitigating GLP-1 RA-induced gastrointestinal side effects, thereby improving adherence and therapeutic efficacy. Further research is needed to evaluate the safety, mechanism, and generalizability of this approach in broader clinical practice.\n                  <\/jats:p>","DOI":"10.2478\/enr-2025-0030","type":"journal-article","created":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T06:01:48Z","timestamp":1765605708000},"page":"260-264","source":"Crossref","is-referenced-by-count":2,"title":["Mirtazapine for gastrointestinal side effects of glucagon-like peptide-1 receptor agonist therapy in older adults"],"prefix":"10.2478","volume":"59","author":[{"given":"Ali R.","family":"Khan","sequence":"first","affiliation":[{"name":"John Sealy School of Medicine , University of Texas Medical Branch at Galveston , TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennifer Wahbah","family":"Makhoul","sequence":"additional","affiliation":[{"name":"Division of Geriatrics, Department of Internal Medicine , University of Texas Medical Branch at Galveston , TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukaila A.","family":"Raji","sequence":"additional","affiliation":[{"name":"Division of Geriatrics, Department of Internal Medicine , University of Texas Medical Branch at Galveston , TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"key":"2026063014554745229_j_enr-2025-0030_ref_001","doi-asserted-by":"crossref","unstructured":"Aktemur G, Cakir BT, Sucu ST, Karabay G, Bucak M, Ulusoy CO, \u015eeyhanli Z, Tonyali NV, Iskender CT. An alternative therapeutic approach for hyperemesis gravidarum that is unresponsive to conventional treatment: Mirtazapine. Research Square; 2024.","DOI":"10.21203\/rs.3.rs-3882240\/v1"},{"key":"2026063014554745229_j_enr-2025-0030_ref_002","doi-asserted-by":"crossref","unstructured":"Anderer S. FDA approves tirzepatide as first drug for obstructive sleep apnea. JAMA 333, 656, 2025.","DOI":"10.1001\/jama.2024.28055"},{"key":"2026063014554745229_j_enr-2025-0030_ref_003","doi-asserted-by":"crossref","unstructured":"Cummings JL, Atri A, Feldman HH, Hansson O, Sano M, Knop FK, Johannsen P, Leon T, Scheltens P. EVOKE and EVOKE+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer\u2019s disease. Alzheimers Res Ther 17, 14, 2025.","DOI":"10.1186\/s13195-024-01666-7"},{"key":"2026063014554745229_j_enr-2025-0030_ref_004","doi-asserted-by":"crossref","unstructured":"Do D, Lee T, Peasah SK, Good CB, Inneh A, Patel U. GLP-1 receptor agonist discontinuation among patients with obesity and\/or type 2 diabetes. JAMA Netw Open. 7, e2413172, 2024.","DOI":"10.1001\/jamanetworkopen.2024.13172"},{"key":"2026063014554745229_j_enr-2025-0030_ref_005","doi-asserted-by":"crossref","unstructured":"Garakani A, Murrough JW, Freire RC, Thom RP, Larkin K, Buono FD, Iosifescu DV. Pharmacotherapy of anxiety disorders: current and emerging treatment options. Front Psychiatry 11, 595584, 2020.","DOI":"10.3389\/fpsyt.2020.595584"},{"key":"2026063014554745229_j_enr-2025-0030_ref_006","doi-asserted-by":"crossref","unstructured":"Gorgojo-Martinez JJ, Mezquita-Raya P, Gorriz JL, Reviriego J. Clinical recommendations to manage gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists in clinical practice. J Clin Med 12, 145, 2022.","DOI":"10.3390\/jcm12010145"},{"key":"2026063014554745229_j_enr-2025-0030_ref_007","doi-asserted-by":"crossref","unstructured":"Hassanein EHM, Althagafy HS, Baraka MA, Abd-alhameed EK, Ibrahim IM. Pharmacological update of mirtazapine: a narrative literature review. Naunyn-Schmiedeberg\u2019s Arch Pharmacol 397, 2603\u20132619, 2024.","DOI":"10.1007\/s00210-023-02818-6"},{"key":"2026063014554745229_j_enr-2025-0030_ref_008","doi-asserted-by":"crossref","unstructured":"Heerspink HJ, Apperloo E, Davies M, Dicker D, Kandler K, Rosenstock J, Sorrig R, Lawson J, Zeuthen N, Cherney D. Effects of semaglutide on albuminuria and kidney function in people with overweight or obesity with or without type 2 diabetes: exploratory analysis from the STEP 1, 2, and 3 trials. Diabetes Care 46, 801\u2013810, 2023.","DOI":"10.2337\/dc22-1889"},{"key":"2026063014554745229_j_enr-2025-0030_ref_009","unstructured":"Jilani TN, Gibbons JR, Faizy RM, Saadabadi A. Mirtazapine. In: StatPearls [Internet]. Treasure Island (FL): Stat-Pearls Publishing; 2024. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK519059\/"},{"key":"2026063014554745229_j_enr-2025-0030_ref_010","doi-asserted-by":"crossref","unstructured":"Kanwar MK, Sunku R, Alruwaili F, Mufti MA, Raji M. Beneficial effects of glucagon-like peptide-1 receptor agonists in patients with asthma: a literature review. Cureus 14, e30812, 2022.","DOI":"10.7759\/cureus.30812"},{"key":"2026063014554745229_j_enr-2025-0030_ref_011","doi-asserted-by":"crossref","unstructured":"Karagiannis T, Tsapas A, Athanasiadou E, Avgerinos I, Liakos A, Matthews DR, Bekiari E. GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis. Diabetes Res Clin Pract 174, 108737, 2021.","DOI":"10.1016\/j.diabres.2021.108737"},{"key":"2026063014554745229_j_enr-2025-0030_ref_012","doi-asserted-by":"crossref","unstructured":"Khan A, Menon R, Corning B, Cohn S, Kumfa C, Raji M. Mirtazapine for gastrointestinal and neuropsychological symptoms in older adults with irritable bowel syndrome. Ther Adv Gastroenterol 18, 17562848241278125, 2024.","DOI":"10.1177\/17562848241278125"},{"key":"2026063014554745229_j_enr-2025-0030_ref_013","doi-asserted-by":"crossref","unstructured":"Khan SS, Ndumele CE, Kazi DS. Discontinuation of glucagon-like peptide-1 receptor agonists. JAMA 333, 113\u2013114, 2025.","DOI":"10.1001\/jama.2024.22284"},{"key":"2026063014554745229_j_enr-2025-0030_ref_014","doi-asserted-by":"crossref","unstructured":"Lalani E, Menon R, Mufti MA, Kumfa C, Raji M. Mirtazapine: a one-stop strategy for treatment of opioid withdrawal symptoms. Cureus 15, e43821, 2023.","DOI":"10.7759\/cureus.43821"},{"key":"2026063014554745229_j_enr-2025-0030_ref_015","doi-asserted-by":"crossref","unstructured":"Lee B, Man KKC, Wong E, Tan T, Sheikh A, Bloom CI. Antidiabetic medication and asthma attacks. JAMA Intern Med 185, 16\u201325, 2025.","DOI":"10.1001\/jamainternmed.2024.5982"},{"key":"2026063014554745229_j_enr-2025-0030_ref_016","doi-asserted-by":"crossref","unstructured":"Liu L, Chen J, Wang L, Chen C, Chen L. Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database. Front Endocrinol 13, 1043789, 2022.","DOI":"10.3389\/fendo.2022.1043789"},{"key":"2026063014554745229_j_enr-2025-0030_ref_017","doi-asserted-by":"crossref","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsboll T; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375, 1834\u20131844, 2016.","DOI":"10.1056\/NEJMoa1607141"},{"key":"2026063014554745229_j_enr-2025-0030_ref_018","doi-asserted-by":"crossref","unstructured":"Meissner WG, Remy P, Giordana C, Maltete D, Derkinderen P, Houeto JL, Anheim M, Benatru I, Boraud T, Brefel-Courbon C, Carriere N, Catala H, Colin O, Corvol JC, Damier P, Dellapina E, Devos D, Dra-pier S, Fabbri M, Ferrier V, et al. Trial of lixisenatide in early Parkinson\u2019s disease. N Engl J Med 390, 1176\u20131185, 2024.","DOI":"10.1056\/NEJMoa2312323"},{"key":"2026063014554745229_j_enr-2025-0030_ref_019","doi-asserted-by":"crossref","unstructured":"Raji MA. Management of chemotherapy-induced side-effects. Lancet Oncol 6, 357, 2005.","DOI":"10.1016\/S1470-2045(05)70182-0"},{"key":"2026063014554745229_j_enr-2025-0030_ref_020","doi-asserted-by":"crossref","unstructured":"Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, Brar R, Baker C, Gluckman TJ, Stucky NL. Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity. JAMA Inter Med 184, 1056\u20131064, 2024.","DOI":"10.1001\/jamainternmed.2024.2525"},{"key":"2026063014554745229_j_enr-2025-0030_ref_021","doi-asserted-by":"crossref","unstructured":"Rodriguez PJ, Zhang V, Gratzl S, Do D, Goodwin Cartwright B, Baker C, Gluckman TJ, Stucky N, Emanuel EJ. Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among US adults with over-weight or obesity. JAMA Netw Open 8, e2457349, 2025.","DOI":"10.1001\/jamanetworkopen.2024.57349"},{"key":"2026063014554745229_j_enr-2025-0030_ref_022","doi-asserted-by":"crossref","unstructured":"Russjan E. The role of peptides in asthma-obesity phenotype. Int J Mol Sci 25, 3213, 2024.","DOI":"10.3390\/ijms25063213"},{"key":"2026063014554745229_j_enr-2025-0030_ref_023","doi-asserted-by":"crossref","unstructured":"Sagiraju SR, Sharma PK, Sharma J. Innovative approaches in mirtazapine delivery: pharmacokinetic simulations, immediate release to controlled release tablets, formulation optimization via D-optimal mixture design. FABAD J Pharmaceut Sci 49, 565\u2013582, 2024.","DOI":"10.55262\/fabadeczacilik.1498118"},{"key":"2026063014554745229_j_enr-2025-0030_ref_024","doi-asserted-by":"crossref","unstructured":"Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M. Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss. JAMA 330, 1795\u20131797, 2023.","DOI":"10.1001\/jama.2023.19574"},{"key":"2026063014554745229_j_enr-2025-0030_ref_025","doi-asserted-by":"crossref","unstructured":"Sultana R, Sissoho F, Kaushik VP, Raji MA. The case for early use of glucagon-like peptide-1 receptor agonists in obstructive sleep apnea patients with comorbid diabetes and metabolic syndrome. Life (Basel) 12, 1222, 2022.","DOI":"10.3390\/life12081222"},{"key":"2026063014554745229_j_enr-2025-0030_ref_026","doi-asserted-by":"crossref","unstructured":"Talbot K, Wang HY. The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer\u2019s disease. Alzheimers Dement 10, S12\u2013S25, 2014.","DOI":"10.1016\/j.jalz.2013.12.007"},{"key":"2026063014554745229_j_enr-2025-0030_ref_027","doi-asserted-by":"crossref","unstructured":"Zhang L, Zhang L, Li L, Holscher C. Semaglutide is neuroprotective and reduces \u03b1-synuclein levels in the chronic MPTP mouse model of Parkinson\u2019s disease. J Parkinsons Dis 9, 157\u2013171, 2019.","DOI":"10.3233\/JPD-181503"}],"container-title":["Endocrine Regulations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/enr-2025-0030","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T21:17:14Z","timestamp":1782854234000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/enr-2025-0030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,1]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12,12]]},"published-print":{"date-parts":[[2025,1,1]]}},"alternative-id":["10.2478\/enr-2025-0030"],"URL":"https:\/\/doi.org\/10.2478\/enr-2025-0030","relation":{},"ISSN":["1336-0329"],"issn-type":[{"value":"1336-0329","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,1]]}}}